Drug lookup | Fillwise

METHOTRIMEPRAZINE

Form:

9 of 9 products shown

5 general benefit · 4 not a benefit

Methoprazine · DIN 02238403 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Methoprazine · DIN 02238403 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2013-06-24 · brand METHOPRAZINE · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 2 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Methoprazine: Formulary list price $0.0721/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0721 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61820 · Verify on the e-Formulary ↗ (DIN 02238403)

Source record

DIN 02238403: Methoprazine Raw flags: sec3=Y Item: 282400041; group id 524; item number 1417; lccId None; manufacturer id AAP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0721; ministry $0.0721 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238403 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61820

Interchangeable products

Nozinan · DIN 01927647 · not recorded

Shortage status: resolved shortage (ended 2023-03-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238403

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Methoprazine · DIN 02238404 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Methoprazine · DIN 02238404 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2013-06-27 · brand METHOPRAZINE · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 5 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Methoprazine: Formulary list price $0.1043/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1043 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02238404: Methoprazine Raw flags: sec3=Y Item: 282400019; group id 524; item number 1418; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1043; ministry $0.1043 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61821

Interchangeable products

Nozinan · DIN 01927655 · not recorded

Shortage status: resolved shortage (ended 2026-07-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238404

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nozinan · DIN 01927698 · 25mg/mL · injection solution-1mL Pk

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Nozinan · DIN 01927698 Manufacturer: Neuraxpharm Arzneimittel GmbH; listing date 1996-10-01 Health Canada: Marketed since 2023-12-19 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Solution · route Intramuscular, Intravenous · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE) 25 MG/ML · company Neuraxpharm arzneimittel gmbh · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price $4.2459/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.2459 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13163 · Verify on the e-Formulary ↗ (DIN 01927698)

Source record

DIN 01927698: Nozinan Raw flags: sec3=Y Item: 282400022; group id 524; item number 1416; lccId None; manufacturer id NEU Source form: Inj Sol-1mL Pk; strength: 25mg/mL Recorded listing: General benefit Source prices (unrounded): $4.2459; ministry $4.2459 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927698 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13163

Shortage status: resolved shortage (ended 2023-09-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01927698

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Methoprazine · DIN 02238405 · 25mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Methoprazine · DIN 02238405 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2014-04-14 · brand METHOPRAZINE · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 25 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Methoprazine: Formulary list price $0.2681/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2681 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02238405: Methoprazine Raw flags: sec3=Y Item: 282400018; group id 524; item number 1419; lccId None; manufacturer id AAP Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2681; ministry $0.2681 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238405 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61822

Interchangeable products

Nozinan · DIN 01927663 · not recorded

Shortage status: resolved shortage (ended 2024-12-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238405

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Methoprazine · DIN 02238406 · 50mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Methoprazine · DIN 02238406 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2014-04-23 · brand METHOPRAZINE · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 50 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Methoprazine: Formulary list price $0.4060/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4060 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02238406: Methoprazine Raw flags: sec3=Y Item: 282400017; group id 524; item number 1420; lccId None; manufacturer id AAP Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.4060; ministry $0.4060 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238406 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61823

Interchangeable products

Nozinan · DIN 01927671 · not recorded

Shortage status: resolved shortage (ended 2026-09-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238406

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nozinan · DIN 01927647 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued 2005-08-01 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Nozinan · DIN 01927647 Manufacturer: Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-01 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 2 MG · company Aventis pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13161 · Verify on the e-Formulary ↗ (DIN 01927647)

Source record

DIN 01927647: Nozinan Raw flags: notABenefit=Y, sec3=Y Item: 282400041; group id 524; item number 1417; lccId None; manufacturer id AVE Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927647 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13161

Interchangeable products

Methoprazine · DIN 02238403 · $0.0721

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01927647

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.

Nozinan · DIN 01927655 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Nozinan · DIN 01927655 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 5 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12438 · Verify on the e-Formulary ↗ (DIN 01927655)

Source record

DIN 01927655: Nozinan Raw flags: notABenefit=Y, sec3=Y Item: 282400019; group id 524; item number 1418; lccId None; manufacturer id SAV Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927655 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12438

Interchangeable products

Methoprazine · DIN 02238404 · $0.1043

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Nozinan · DIN 01927663 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Nozinan · DIN 01927663 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 25 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12439 · Verify on the e-Formulary ↗ (DIN 01927663)

Source record

DIN 01927663: Nozinan Raw flags: notABenefit=Y, sec3=Y Item: 282400018; group id 524; item number 1419; lccId None; manufacturer id SAV Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927663 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12439

Interchangeable products

Methoprazine · DIN 02238405 · $0.2681

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Nozinan · DIN 01927671 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Nozinan · DIN 01927671 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 50 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12440 · Verify on the e-Formulary ↗ (DIN 01927671)

Source record

DIN 01927671: Nozinan Raw flags: notABenefit=Y, sec3=Y Item: 282400017; group id 524; item number 1420; lccId None; manufacturer id SAV Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927671 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12440

Interchangeable products

Methoprazine · DIN 02238406 · $0.4060

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, TRIAZOLAM 28:24 Sedatives and Hypnotics

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS NOZINAN (methotrimeprazine hydrochloride injection) is indicated for:  Psychotic disturbances: acute and chronic schizophrenias, senile psychoses, manic-depressive syndromes.  Analgesic: In pain due to cancer, zona, trigeminal neuralgia, neurocostal neuralgia, in phantom limb pains, muscular discomforts and as post-operative analgesic adjunct.  Antiemetic: For the treatment of nausea and vomiting of central origin.  Sedative: For the management of insomnia. 1.1 Pediatrics Pediatrics (<1 year of age): Contraindicated See 2 CONTRAINDICATIONS. Pediatrics (1 – 18 years of age): 4.2 4.2 Recommended Dose and Dosage Adjustment 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7 WARNINGS AND PRECAUTIONS, 4.2 4.2 Recommended Dose and Dosage Adjustment NOZINAN is not indicated for the treatment of patients with dementia. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. https://pdf.hres.ca/dpd_pm/00073362.PDF PM date: NOV 15, 2023 Source product: NOZINAN; DIN 01927698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Nozinan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026